Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD TSXV Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2025-04-15 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (F).pdf
Regulatory Filings Classification · 1% confidence The document is an Annex 52-109AE2 attestation by the CFO for an emerging issuer, certifying the interim financial report and MD&A. It is not the interim report itself but a required regulatory certificate under Canadian NI 52-109. There is no dedicated category for attestation certificates, and it is not an Annual Report or Interim Report or Audit Report. It fits as a general regulatory filing. Therefore, classification is RNS.
2025-04-15 French
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a regulatory “Form 52-109FV2” certificate by the CFO certifying the interim filings (interim financial report and MD&A) under Canadian securities regulation. It does not include the interim financial statements or MD&A themselves (so it’s not the IR), nor is it an announcement of report publication (RPA) or an earnings release. It is a regulatory‐required certification that does not fit any more specific category, making it a miscellaneous regulatory filing. Therefore, it falls under Regulatory Filings (RNS).
2025-04-15 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis – for the three-month and six-month periods ended January 31, 2025.” It provides management’s narrative overview of business, financial performance, forward-looking statements and trends for Q2 of fiscal 2025. This is the classic MD&A section separate from audited financial statements, matching the definition of a Management Report (MDA), not the full interim report, not an earnings release. Therefore, it should be classified under code MDA.
2025-04-15 English
Interim MD&A - French.pdf
Management Reports Classification · 1% confidence The provided document is titled “Rapport de gestion – pour les périodes de trois mois et six mois terminées le 31 janvier 2025,” which in French corresponds to a Management Discussion & Analysis (MD&A) covering interim periods. It discusses the company’s financial position, operating results, R&D activities, performance comparisons to prior periods, and forward-looking statements, and it is meant to be read alongside the unaudited interim consolidated financial statements. This aligns precisely with the Management Reports category (MDA).
2025-04-15 French
Interim financial statements/report – French.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive set of interim consolidated financial statements for Groupe Santé Devonian Inc. for the three-month and six-month periods ended January 31, 2025. It includes the consolidated statement of financial position, statement of net loss and comprehensive loss, statement of changes in equity, statement of cash flows, and detailed notes to the financial statements. This meets the definition of an Interim/Quarterly Report (IR) as it contains substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-04-15 French
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim Consolidated Financial Statements' for the three-month and six-month periods ended January 31, 2025. It contains comprehensive financial statements, including the Statement of Financial Position, Statement of Net Loss and Comprehensive Loss, Statement of Changes in Equity, and Statement of Cash Flows, along with detailed explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-04-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.